Metabolic syndrome – organoprotective influence of angiotensin II receptor antagonists

Danuta Pupek-Musialik; Katarzyna Musialik

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors

5/2007
vol. 10

Send email

Copy url:

abstract:

Metabolic syndrome – organoprotective influence of angiotensin II receptor antagonists

Danuta Pupek-Musialik

,

Katarzyna Musialik

Przew Lek 2007; 5: 63-69

Online publish date: 2007/09/07

View full text Get citation

Recently the International Diabetes Federation (IDF) has proposed a new definition of metabolic syndrome. Hypertension commonly occurs as part of a complex disorder of carbohydrate and lipid metabolism. Metabolic syndrome increases the likelihood of developing type 2 diabetes by five to nine fold and cardiovascular disease by two to four fold. Angiotensin II receptor blockers (ARBs) are used for the treatment and prevention of cardiovascular disease. Recent preclinical studies indicate that the ARB telmisartan acts as a selective peroxisome proliferator-activated receptor gamma (PPAR-d) modulator. Telmisartan functioned as a partial agonist of PPAR-δ and achieved 25–30% of maximal receptor activation attained with conventional PPAR-δ ligands. Telmisartan could have a central role in prevention and treatment of metabolic syndrome and diabetes

keywords:

Metabolic syndrome – organoprotective influence of angiotensin II receptor antagonists

Danuta Pupek-Musialik , Katarzyna Musialik

metabolic syndrome, angiotensin II receptor antagonists, hypertension, diabetes

Danuta Pupek-Musialik

,

Katarzyna Musialik